AssetMark Inc’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $1.48M | Buy |
95,720
+9,181
| +11% | +$142K | ﹤0.01% | 839 |
|
2025
Q1 | $1.29M | Buy |
86,539
+372
| +0.4% | +$5.53K | ﹤0.01% | 820 |
|
2024
Q4 | $1.14M | Buy |
86,167
+5,185
| +6% | +$68.7K | ﹤0.01% | 823 |
|
2024
Q3 | $1.15M | Buy |
80,982
+4,500
| +6% | +$64K | ﹤0.01% | 764 |
|
2024
Q2 | $990K | Buy |
76,482
+890
| +1% | +$11.5K | ﹤0.01% | 769 |
|
2024
Q1 | $1.05M | Buy |
75,592
+3,864
| +5% | +$53.7K | ﹤0.01% | 721 |
|
2023
Q4 | $1.02M | Buy |
71,728
+193
| +0.3% | +$2.75K | ﹤0.01% | 669 |
|
2023
Q3 | $1.11M | Buy |
71,535
+1
| +0% | +$15 | ﹤0.01% | 598 |
|
2023
Q2 | $1.12M | Buy |
71,534
+4,946
| +7% | +$77.7K | ﹤0.01% | 590 |
|
2023
Q1 | $1.1M | Buy |
66,588
+51,648
| +346% | +$851K | ﹤0.01% | 587 |
|
2022
Q4 | $233K | Buy |
14,940
+1,090
| +8% | +$17K | ﹤0.01% | 798 |
|
2022
Q3 | $180K | Buy |
13,850
+988
| +8% | +$12.8K | ﹤0.01% | 776 |
|
2022
Q2 | $181K | Sell |
12,862
-960
| -7% | -$13.5K | ﹤0.01% | 753 |
|
2022
Q1 | $198K | Buy |
13,822
+1,152
| +9% | +$16.5K | ﹤0.01% | 731 |
|
2021
Q4 | $173K | Buy |
12,670
+667
| +6% | +$9.11K | ﹤0.01% | 728 |
|
2021
Q3 | $197K | Buy |
+12,003
| New | +$197K | ﹤0.01% | 570 |
|
2021
Q1 | – | Sell |
-62,049
| Closed | -$1.13M | – | 1523 |
|
2020
Q4 | $1.13M | Buy |
62,049
+24,680
| +66% | +$449K | 0.01% | 343 |
|
2020
Q3 | $667K | Buy |
37,369
+9,134
| +32% | +$163K | ﹤0.01% | 375 |
|
2020
Q2 | $506K | Buy |
28,235
+8,843
| +46% | +$158K | ﹤0.01% | 384 |
|
2020
Q1 | $294K | Sell |
19,392
-70,986
| -79% | -$1.08M | ﹤0.01% | 431 |
|
2019
Q4 | $1.78M | Buy |
90,378
+43,104
| +91% | +$850K | 0.01% | 317 |
|
2019
Q3 | $813K | Buy |
47,274
+39,829
| +535% | +$685K | 0.01% | 331 |
|
2019
Q2 | $132K | Buy |
7,445
+6,075
| +443% | +$108K | ﹤0.01% | 549 |
|
2019
Q1 | $28K | Buy |
+1,370
| New | +$28K | ﹤0.01% | 815 |
|